6
KAEF0203.TXT

KAEF
Kimia Farma
Af          :
Sector Code : 53
Sector Name : PHARMACEUTICALS

(In thousand rupiah except Par Value, Closing Price and Ratios)

Financial Statement Date    : 31-Mar-2002
Fiscal Year Ends            : Dec
Months Covered in Income St : 3

Summary of Balance Sheet
  Receivables               :     126,560,040.50
  Inventories               :     302,275,986.71
  Current Assets            :     669,884,962.34
  Fixed Assets              :     335,495,067.77
  Other Asstes              :      12,230,584.70
  Total Assets              :   1,052,859,208.30
  Current Liabilities       :     256,998,950.34
  Longterm Liabiities       :      49,833,255.80
  Total Liabilities         :     306,832,206.14
  Authorized                :      20,000,000.00
  Paid-up Capital           :     555,400,000.00
  Par Value                 :                100
  Paid-up Capital Shares    :       5,554,000.00
  Retained Earnings         :     146,917,479.15
  Total Equity              :     746,027,002.15
  Minority Interest         :               0.00

Summary of Income Statement
  Total Sales               :     288,040,659.39
  Cost of Good Sold         :     199,429,056.87
  Gross Profit              :      88,611,602.52
  Operating Profit          :      17,169,634.85
  Other Income              :      -1,554,006.35
  Eearning Before Tax       :      15,615,628.50
  Tax                       :       3,578,407.23
  Net Income                :      12,037,221.26
  Closing Price             :             230.00

Per Share Data (Rp)
  Eps                       :               8.67
  Book Value                :             134.32

Financial Ratios
  Debt Equity Ratio (X)     :                .41
  Roa (%)                   :               4.57
  Roe (%)                   :               6.45
  Npm (%)                   :               4.18
  Opm (%)                   :               5.96

Cash Flow
  CF from Operating Activities                        :    -156,198,323.52
  CF from Investing Activities                        :      -7,916,016.97
  CF from Financing Activities                        :      -9,974,735.93
  Net Increase in Cash & Cash Equivalent              :    -174,089,076.42
  Cash & Cash Equivalent at The Beginning of The Year :     357,309,526.30
  Cash & Cash Equivalent at The End of The Year       :     183,220,449.88

 
 
 
